CBD matched a standard antipsychotic for treating schizophrenia symptoms — with dramatically fewer side effects — by enhancing the brain's own endocannabinoid system

PANSS total improvement: CBD 30.5 (±16.4) vs amisulpride 30.1 (±24.7), p=0.884. Response rates (≥20% improvement): 75% CBD vs 74% amisulpride. CBD significantly better on: extrapyramidal symptoms (p=0.006), weight gain (p=0.010), prolactin elevation (p<0.001). Anandamide levels increased significantly with CBD vs amisulpride (p<0.001 at day 28). Anandamide increase correlated with symptom improvement in CBD group (p=0.0012) but not amisulpride group (p=0.64).

Double-blind, randomized, parallel-group, Phase II active-controlled trial (CBD-CT1; NCT00628290). 42 acutely exacerbated schizophrenic inpatients randomized 1:1 to CBD 800 mg/day or amisulpride 800 mg/day for 28 days. Both escalated from 200 mg/day over first week. Lorazepam permitted for agitation. Assessed with PANSS (primary), BPRS, CGI, EPS scale, metabolic markers. MMRM statistical analysis. Approved by University of Cologne Ethics Committee. Funded by Stanley Medical Research Institute and NIDA.

This is the first randomized trial showing CBD can match a conventional antipsychotic for efficacy while producing dramatically fewer side effects — and through a completely novel mechanism (FAAH inhibition / anandamide enhancement rather than dopamine blockade). Antipsychotic side effects drive medication non-adherence, which drives relapse. A treatment with equivalent efficacy and minimal side effects would transform schizophrenia management.

Every antipsychotic since chlorpromazine (1952) has worked by blocking dopamine. Leweke showed CBD works through an entirely different mechanism — enhancing the endocannabinoid system. If validated in larger trials, this would represent the first genuinely new approach to treating psychosis in seven decades. McGuire's 2018 Phase II add-on trial (88 patients, Am J Psychiatry) confirmed the signal but with smaller effect sizes.

Only 42 patients — too small for definitive conclusions or rare adverse event detection. Non-inferiority could not be formally demonstrated (confidence intervals too wide). Study terminated early due to funding expiration. Cannabinoid-positive patients excluded, limiting recruitment. Baseline lorazepam use was significantly higher in the amisulpride group (p=0.006). CBD monotherapy — no data on long-term use or treatment-resistant cases.